Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Brian Elsbernd Insider Profile
11 Followers
Brian Elsbernd, Chief Compliance/Legal Officer at Catalyst Pharma, holds 176.52K shares in Catalyst Pharma (Ticker: CPRX).
Brian Elsbernd Catalyst Pharma (CPRX)Chief Compliance/Legal Officer
Catalyst Pharma (CPRX)
Chief Compliance/Legal Officer
Ranked #57,300 out of 99,797 Corporate Insiders
Profitable Transactions
3 out of 4 Profitable Transactions
Average Return
-5.20%
Average return per transaction
Time Frame
Compare to
Insider Roles
Chief Compliance/Legal Officer
Roles that Brian Elsbernd holds in companies
Most Profitable Insider Trade
The most profitable trade made by Brian Elsbernd
Brian Elsbernd's Trading History
List of latest transactions for each holding click on a transaction to see Brian Elsbernd's performance on stock
You May Also Like
Brian Elsbernd insider profile FAQ
What is the percentage of profitable transactions made by Brian Elsbernd?
The percentage of profitable transactions made by Brian Elsbernd is 75%.
What is the average return per transaction made by Brian Elsbernd?
The average return per transaction made by Brian Elsbernd is -5.20%.
What stocks does Brian Elsbernd hold?
Brian Elsbernd holds: CPRX stocks.
What was Brian Elsbernd’s latest transaction?
Brian Elsbernd latest transaction was an Uninformative Buy of $116.24K.
What was Brian Elsbernd's most profitable transaction?
Brian Elsbernd’s most profitable transaction was an Informative Sell of CPRX stock on November 15, 2022. The return on the trade was 14.00%.
What is Brian Elsbernd's role in Catalyst Pharma?
Brian Elsbernd's role in Catalyst Pharma is Chief Compliance/Legal Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.